Estimation of metabolic factors related to insulin resistance and metabolic syndrome in young people
Estimation of metabolic factors related to insulin resistance and metabolic syndrome in young people
复制标题
DOI：
10.1080/00365513.2018.1469787
复制
发表时间：
2018-01-01
影响因子：
2.1
通讯作者：
Piwowar, Agnieszka
中科院分区：
文献类型：
--
作者：
Placzkowska, Sylwia;Pawlik-Sobecka, Lilla;Piwowar, Agnieszka
近几十年来的文明发展导致与胰岛素抵抗相关的各种代谢紊乱在年轻人中的发病率增加。确定胰岛素抵抗指数的决策界限，特别是在年轻人中，是临床实践中的一个重大挑战。本研究的目的是估计与胰岛素抵抗和代谢综合征（MS）特征相关的代谢因素，在年轻的，明显健康的人。此外，我们还评估了从C肽浓度获得的HOMA 1-IR、HOMA 2-IR、HOMA 2用于MS鉴定的患者的最佳决策限。349名年龄在18-31岁的表面上健康的人（260名女性和89名男性）参加了这项研究。目前的代谢，人体测量和临床参数的分析观察到他们在集群涵盖的MS识别的标准，但MS在这组中只是部分相关的胰岛素抵抗。HOMA 1-IR决策限估计可能成为有用的在年轻的，显然健康的人代谢紊乱的解释。胰岛素抵抗的措施，可以提供一个可靠的MS的早期预测可能会提供一个机会，煽动预防措施的显着临床效用。
Civilizational developments occurring during recent decades have resulted in an increased incidence of a variety of metabolic disorders related to insulin resistance in younger people. The determination of decision limits for insulin resistance indices, especially among young people, is a significant challenge in clinical practice. The aim of this study was the estimation of metabolic factors related to their relationship to insulin resistance and metabolic syndrome (MS) features in young, apparently healthy people. Moreover, we evaluated the optimal decision limits for patients with MS identification for HOMA1-IR, HOMA2-IR, HOMA2 obtained from C-peptide concentrations. 349 apparently healthy people aged 18-31 (260 women and 89 men), were enrolled in this study. The present analysis of metabolic, anthropometric and clinical parameters observed them in clusters covering the criteria of MS recognition, but MS in this group was only partially related to insulin resistance. The HOMA1-IR decision limit estimation is likely to became be useful in the prognostication of metabolic disturbances in young, apparently healthy people. A measure of insulin resistance that can provide a reliable early prediction of MS is likely to provide an opportunity for instigating preventive measures of significant clinical utility.